Victoria C Pham - JoVE Visualize

Showing results (21-30 of 25) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 25 results.

Science Immunology|April 22, 2018

Tumor suppressor BAP1 is essential for thymic development and proliferative responses of T lymphocytesTeresita L Arenzana, Steve Lianoglou, Akiko Seki, et al.

Nature|September 24, 2020

Integration of innate immune signalling by caspase-8 cleavage of N4BP1Alexander D Gitlin, Klaus Heger, Alexander F Schubert, et al.

Science (New York, N.Y.)|August 11, 2012

Loss of the tumor suppressor BAP1 causes myeloid transformationAnwesha Dey, Dhaya Seshasayee, Rajkumar Noubade, et al.

Science Signaling|April 20, 2017

The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammationKate Senger, Victoria C Pham, Eugene Varfolomeev, et al.

American Journal of Hematology|January 3, 2023

Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib studyElisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.

Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 25 results.

Science Immunology|April 22, 2018

Tumor suppressor BAP1 is essential for thymic development and proliferative responses of T lymphocytesTeresita L Arenzana, Steve Lianoglou, Akiko Seki, et al.

Nature|September 24, 2020

Integration of innate immune signalling by caspase-8 cleavage of N4BP1Alexander D Gitlin, Klaus Heger, Alexander F Schubert, et al.

Science (New York, N.Y.)|August 11, 2012

Loss of the tumor suppressor BAP1 causes myeloid transformationAnwesha Dey, Dhaya Seshasayee, Rajkumar Noubade, et al.

Science Signaling|April 20, 2017

The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammationKate Senger, Victoria C Pham, Eugene Varfolomeev, et al.

American Journal of Hematology|January 3, 2023

Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib studyElisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.

Pageof 3